As ALCL is divided based on the presence of translocation that fuses the anaplastic lymphoma kinase (ALK) gene to NPM, ALK inhibitors have been evaluated in patients with ALK + ALCL. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.